Harel Insurance Investments & Financial Services’s Protalix BioTherapeutics PLX Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-26,000	Closed	-$40K	–	492
2025 Q2	$40K	Buy	+26,000	New	+$53.2K	﹤0.01%	362
2017 Q4	–	Sell	-2,000	Closed	-$12K	–	496
2017 Q3	$12K	Hold	2,000	–	–	﹤0.01%	387
2017 Q2	$17K	Sell	2,000 -335	-14%	-$3.15K	﹤0.01%	360
2017 Q1	$25K	Sell	2,335 -1,665	-42%	-$15K	﹤0.01%	302
2016 Q4	$18K	Hold	4,000	–	–	﹤0.01%	260
2016 Q3	$23K	Buy	+4,000	New	+$24.9K	﹤0.01%	294

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harel Insurance Investments & Financial Services's PLX Position: Q3 2025 in Review

Harel Insurance Investments & Financial Services sold out of Protalix BioTherapeutics (PLX) in Q3 2025, closing a stake of 26,000 shares — an estimated $40K sold.

Harel Insurance Investments & Financial Services first reported a position in PLX in Q3 2016 and held it in 6 quarters. The position peaked at $40K in Q2 2025. 77 funds tracked by Wall St. Rank hold PLX as of Q3 2025.

Harel Insurance Investments & Financial Services reported no remaining Protalix BioTherapeutics position as of Q3 2025 after selling out during the quarter.
Harel Insurance Investments & Financial Services sold 26,000 Protalix BioTherapeutics shares in Q3 2025, an estimated $40K.
Harel Insurance Investments & Financial Services first reported a position in Protalix BioTherapeutics in Q3 2016 and held it in 6 quarters.
Harel Insurance Investments & Financial Services's Protalix BioTherapeutics position peaked at $40K in Q2 2025.
77 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2025.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q3 2025, filed 29 Oct 2025.